| Literature DB >> 30370021 |
Juho Loponen1,2, Pinja Ilmarinen1, Leena E Tuomisto1, Onni Niemelä3, Minna Tommola1, Pentti Nieminen4, Lauri Lehtimäki2,5, Hannu Kankaanranta1,2.
Abstract
Background: There is a lack of knowledge on the association between daily physical activity and lung function in patients with asthma. Objective: This study aims to examine the association between daily physical activity and asthma control, lung function, and lung function decline in patients with adult-onset asthma. Design: This study is part of Seinäjoki Adult Asthma Study (SAAS), where 201 patients were followed for 12 years after asthma diagnosis. Daily physical activity was assessed at follow-up by a structured questionnaire and used to classify the population into subgroups of low (≤240 min) or high (>240 min) physical activity. Three spirometry evaluation points were used: 1. diagnosis, 2. the maximum lung function during the first 2.5 years after diagnosis (Max0-2.5), 3. follow-up at 12 years.Entities:
Keywords: Asthma; FEV1 decline; adult; adult-onset; lung function decline; physical activity; systemic inflammation
Year: 2018 PMID: 30370021 PMCID: PMC6201802 DOI: 10.1080/20018525.2018.1533753
Source DB: PubMed Journal: Eur Clin Respir J ISSN: 2001-8525
Figure 1.Flow chart of the study.
Figure 2.Representation of the three lung function measurement points.
Basic subject characteristics by physical activity groups.
| ≤240 min of physical activity/day | >240 min of physical activity/day | ||
|---|---|---|---|
| Number of patients | 74 | 127 | |
| Age (years) | 61 (13) | 57 (14) | |
| Age of onset (years) | 49 (13) | 44 (14) | |
| Males | 39 (53%) | 45 (35%) | |
| Duration of daily physical activity (min) | 135 (90–180) | 480 (360–600) | |
| Patients exercising at least 3 times per week | 43 (58%) | 69 (54%) | 0.660 |
| BMI (kg/m2) | 28.7 (5.2) | 28.4 (5.8) | 0.807 |
| Ex or current smoker | 38 (51%) | 68 (54%) | 0.772 |
| Pack years (of ex- and current smokers) | 20 (10–32) | 15 (4–27) | 0.067 |
| Post-brochodilator FEV1/FVC <0.7 and at least 10 pack years | 17 (24%) | 16 (13%) | |
| Patients with at least one co-morbidity | 51 (70%) | 76 (60%) | 0.172 |
| Number of co-morbidities, COPD included | 1 (0–3) | 1 (0–2) | 0.091 |
| Daily ICS users | 60 (81%) | 93 (73%) | 0.233 |
| ICS dose (μg budesonide equivalent) | 800 (400–1000) | 800 (280–1000) | 0.393 |
| Patients who received oral corticosteroids | 30 (41%) | 35 (28%) | 0.062 |
| Daily add-on medication (includes LABA) | 39 (53%) | 62 (49%) | 0.661 |
| Atopy | 18 (27%) | 49 (42%) | 0.055 |
*Statistical significances were evaluated using Mann-Whitney test, independent samples t-test or Chi-square test, respectively. Results are displayed as median (interquartile range), mean (SD), or n (%). BMI: body mass index; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; COPD: chronic obstructive pulmonary disease; ICS: inhaled corticosteroid; LABA: long acting beta-adrenoceptor agonist.
Lung function at follow-up by physical activity groups.
| ≤240 min of physical activity/day | >240 min of physical activity/day | ||
|---|---|---|---|
| FVC (%ref) pre-BD | 95 (16) | 98 (15) | 0,222 |
| FVC (%ref) post-BD | 97 (16) | 99 (14) | 0,269 |
| FEV1 (%ref) pre-BD | 81 (19) | 88 (16) | |
| FEV1 (%ref) post-BD | 84 (18) | 91 (16) | |
| FEV1/FVC pre-BD | 0.71 (0.63–0.78) | 0.75 (0.69–0.79) | |
| FEV1/FVC post-BD | 0.72 (0.65–0.79) | 0.77 (0.71–0.81) |
*Statistical significances were evaluated using Mann-Whitney test or independent samples t-test. Results are displayed as median (interquartile range) or mean (SD).FVC: forced vital capacity; BD: bronchodilator; FEV1: forced expiratory volume in 1 s.
Annual pre-BD lung function decline from Max0-2.5 to follow-up by physical activity group.
| ≤240 min of physical activity/day | >240 min of physical activity/day | ||
|---|---|---|---|
| ΔFVC/year, pre-BD (ml) | −43.6 (42.1) | −29.3 (39.7) | |
| ΔFVC/year, pre-BD (%) | −0.12 (1.14) | 0.03 (0.95) | 0.325 |
| ΔFEV1/year, pre-BD (ml) | −58.8 (37.3) | −41.4 (34.2) | |
| ΔFEV1/year, pre-BD (%) | −0.83 (1.13) | −0.39 (0.97) | |
| ΔFEV1/ΔFVC -ratio/year, pre-BD | −0.0052 (−0.0101 to −0.0019) | −0.0041 (−0.0075 to −0.0016) | 0.062 |
*Statistical significances were evaluated using Mann-Whitney test or independent samples t-test. Results are displayed as median (interquartile range) or mean (SD). FVC: forced vital capacity, BD: bronchodilator, FEV1: forced expiratory volume in 1 s.
Figure 3.Changes in mean Pre-BD FEV1 (mL) during 12 years of follow-up in the groups of <240 or ≥240 min of daily physical activity.
Asthma control and symptoms at follow-up.
| ≤240 min of physical activity/day | >240 min of physical activity/day | ||
|---|---|---|---|
| Uncontrolled asthma** | 27 (36.5) | 32 (25.2) | 0.234 |
| ACT score at follow-up | 22 (17–24) | 22 (20–24) | 0.159 |
| ACT Q2 shortness of breath at least 3–6 times/week | 22 (29.7) | 16 (12.6) | |
| ACT Q5 asthma somewhat controlled, poorly controlled, not at all controlled | 25 (33.8) | 25 (19.7) |
*Statistical significances were evaluated using Chi-square test or Mann-Whitney test. Results are displayed as n (%) or median (interquartile range). ACT: asthma control test.
**As assessed according to GINA 2010 as previously described [18].
Association of explanatory factors with lung function decline from Max0-2.5 to follow-up in multiple linear regression.
| Variable | Estimate (∆ml) | 95% Confidence Interval | |
|---|---|---|---|
| (Constant) | −22.39 | −69.16 to 24.39 | 0.346 |
| Physical activity over 240 min/day | 17.90 | 8.00 to 27.80 | |
| Sex (female) | 13.12 | 3.08 to 23.16 | |
| Age at follow-up | −0.23 | −0.59 to 0.13 | 0.209 |
| BMI at follow-up | −1.01 | −2.02 to −0.01 | |
| Not a daily ICS user at follow-up | 1.40 | −10.15 to 12.95 | 0.811 |
| Atopy | −11.38 | −21.72 to −1.04 | |
| Ever smoker at follow-up | −1.97 | −11.70 to 7.76 | 0.690 |
n = 173 (outliers: n = 7, missing data: n = 21), BMI: body mass index, ICS: inhaled corticosteroid.